Development of autoantibodies in the TrialNet Natural History Study
about
Evaluation of Candidate Biomarkers of Type 1 Diabetes via the Core for Assay ValidationNetwork for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetesType 1 diabetes mellitus.HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease ProgressionB cells and type 1 diabetes ...in mice and men.Neuronal T-cell autoreactivity is amplified in overweight children with new-onset insulin-requiring diabetes.β cell death and dysfunction during type 1 diabetes development in at-risk individuals.ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study.Insulitis in the pathogenesis of type 1 diabetesAn important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age.Risk Factors for Type 1 Diabetes Recurrence in Immunosuppressed Recipients of Simultaneous Pancreas-Kidney Transplants.The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants.Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.The multiple origins of Type 1 diabetes.Role of B lymphocytes in the pathogenesis of type 1 diabetes.Can we prevent type 1 diabetes?Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests.Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study.Oxidative Modifications in Tissue Pathology and Autoimmune Disease.The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults.Understanding and preventing type 1 diabetes through the unique working model of TrialNet.Have we pushed the needle for treatment of Type 1 diabetes?B cells in type 1 diabetes mellitus and diabetic kidney disease.Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives.HLA-G 14-bp polymorphism affects the age of onset in Type I Diabetes Mellitus.Abnormal T Cell Frequencies, Including Cytomegalovirus-Associated Expansions, Distinguish Seroconverted Subjects at Risk for Type 1 Diabetesβ Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis
P2860
Q26783728-D76A2AC7-71BA-4083-B13F-8D4631FA2E87Q27009104-5ADB45F3-9365-4AE4-81D8-19496876D5DAQ30235021-4291BB6E-28DE-40F9-BA87-079309C0A37AQ30732418-2C0B056D-EB5B-419F-B07D-6F8570E32AF4Q33926306-171E134A-1EF4-4009-9886-9A2981779E42Q34762316-7B831021-5564-4CB3-ACDB-F60177590846Q35183950-134B41DF-9996-4281-8943-A02CAE8B1749Q37062268-92352B79-0468-4D36-839C-68E12155B001Q37103789-EAE51E57-1AE4-4D3A-8FE7-2D3ACAFBFA2BQ37261014-2D5EAC7D-0F68-49F9-8A61-88B67EE7A2C1Q37316533-CC859A5C-F553-47B2-A39C-6F4145206AD0Q37368421-045B7470-EBC6-4081-B041-AFE44182EAFCQ37659402-4EC92DA2-AF9B-481C-AD51-2AC25D1D92B0Q38062580-1C7796E5-A79F-4C73-87B7-82D1468105A1Q38246133-0036D17D-78AD-479C-A118-8F5BDE7755ABQ38586895-9086E751-EDD0-46F7-B970-CDBF05ADF3D2Q38679602-9622F128-07B5-4A3C-9039-CCBD85CE7579Q38837965-9B445ACF-A2E6-4A87-AD98-6BD31249B728Q40954993-DC00CB78-FA3F-4E00-97DA-5D187F0BA0DBQ45989245-67EE7976-8157-46AF-997D-A4EAFF9E3A9EQ46140989-99479AB9-A078-45F3-BCD8-B2E896462D9FQ46486153-BC0F4CAF-BA59-4D3E-9B54-7092A8D8C83FQ47907621-B085C114-12FF-4B39-A7D5-DC3585DAB1F9Q50077505-7F84AA61-6188-436F-8204-0781F76DFD16Q50988456-B666865A-90CE-4E81-B209-7FD6FEDCC514Q53121646-486ADA6C-7077-4721-BFF0-5CEC783488D5Q58580465-4E473178-8170-4912-9CEC-5C984106F22FQ58792346-66A474BA-C3BA-42C7-AE21-C9264B8C2637
P2860
Development of autoantibodies in the TrialNet Natural History Study
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Development of autoantibodies in the TrialNet Natural History Study
@ast
Development of autoantibodies in the TrialNet Natural History Study
@en
type
label
Development of autoantibodies in the TrialNet Natural History Study
@ast
Development of autoantibodies in the TrialNet Natural History Study
@en
prefLabel
Development of autoantibodies in the TrialNet Natural History Study
@ast
Development of autoantibodies in the TrialNet Natural History Study
@en
P2093
P2860
P356
P1433
P1476
Development of autoantibodies in the TrialNet Natural History Study
@en
P2093
Craig A Beam
Desmond A Schatz
Jay M Sosenko
Jay S Skyler
Jeffrey L Mahon
Jeffrey P Krischer
Michael J Haller
TrialNet Natural History Study Group
P2860
P304
P356
10.2337/DC11-0560
P407
P50
P577
2011-07-12T00:00:00Z